Novartis AG PE Ratio 2006-2018 | NVS

Current and historical p/e ratio for Novartis AG (NVS) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Novartis AG PE ratio as of April 19, 2019 is 15.01.
Novartis AG PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-04-18 76.41 14.23
2018-12-31 85.81 $5.37 15.98
2018-09-30 86.16 $5.70 15.12
2018-06-30 75.54 $5.89 12.83
2018-03-31 80.85 $3.41 23.71
2017-12-31 81.04 $3.25 24.94
2017-09-30 82.87 $2.81 29.49
2017-06-30 80.57 $2.74 29.40
2017-03-31 71.69 $2.66 26.95
2016-12-31 67.87 $2.80 24.24
2016-09-30 73.57 $2.84 25.91
2016-06-30 76.88 $2.80 27.46
2016-03-31 67.50 $2.80 24.11
2015-12-31 77.20 $7.28 10.60
2015-09-30 82.47 $7.45 11.07
2015-06-30 88.23 $7.99 11.04
2015-03-31 88.48 $8.27 10.70
2014-12-31 80.86 $4.14 19.53
2014-09-30 82.14 $4.35 18.88
2014-06-30 79.00 $3.94 20.05
2014-03-31 74.19 $3.94 18.83
2013-12-31 67.88 $3.72 18.25
2013-09-30 64.78 $3.73 17.37
2013-06-30 59.71 $3.84 15.55
2013-03-31 60.16 $3.92 15.35
2012-12-31 51.50 $3.90 13.21
2012-09-30 49.84 $3.55 14.04
2012-06-30 45.48 $3.55 12.81
2012-03-31 45.08 $3.55 12.70
2011-12-31 44.52 $3.80 11.72
2011-09-30 43.43 $4.26 10.20
2011-06-30 47.59 $4.24 11.22
2011-03-31 42.33 $4.19 10.10
2010-12-31 44.02 $4.28 10.29
2010-09-30 43.07 $4.35 9.90
2010-06-30 36.08 $4.28 8.43
2010-03-31 40.40 $4.11 9.83
2009-12-31 39.21 $3.69 10.63
2009-09-30 36.29 $3.34 10.87
2009-06-30 29.38 $3.34 8.80
2009-03-31 27.25 $3.44 7.92
2008-12-31 34.33 $3.59 9.56
2008-09-30 36.45 $3.34 10.91
2008-06-30 37.97 $5.39 7.04
2008-03-31 35.34 $5.26 6.72
2007-12-31 36.40 $5.16 7.05
2007-09-30 36.83 $5.45 6.76
2007-06-30 37.58 $3.28 11.46
2007-03-31 36.61 $3.15 11.62
2006-12-31 37.78 $3.06 12.35
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $176.507B $51.900B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $368.953B 16.73
Pfizer (PFE) United States $234.424B 13.13
Merck (MRK) United States $197.334B 16.86
Eli Lilly (LLY) United States $119.326B 20.72
Novo Nordisk (NVO) Denmark $118.242B 19.13
AbbVie (ABBV) United States $114.422B 9.81
Sanofi (SNY) France $103.609B 12.79
GlaxoSmithKline (GSK) United Kingdom $98.852B 12.98
AstraZeneca (AZN) United Kingdom $98.276B 11.21
Bristol-Myers Squibb (BMY) United States $74.378B 11.44